<DOC>
	<DOCNO>NCT00245765</DOCNO>
	<brief_summary>A study ass safety efficacy 2 different dos CDP870 versus placebo , administer 12 week , patient suffer moderate severe chronic plaque psoriasis , extend 12 24 week follow-up .</brief_summary>
	<brief_title>Efficacy Study CDP870 Subjects With Chronic Plaque Psoriasis Who Are Candidate Systemic Therapy and/or Phototherapy/Photochemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>men woman &gt; 18 year ; Chronic plaque psoriasis stable least 3 month moderate severe least 6 month ; PASI ≥ 12 BSA ≥ 10 % ; Candidates systemic psoriasis therapy and/or phototherapy and/or photochemotherapy ; Erythrodermic , guttate , palmar plantar , generalize pustular form psoriasis ; A history chronic infection , recent serious lifethreatening infection ( within six month , include herpes zoster ) , current sign symptom may indicate infection ( e.g . fever , cough ) ; White blood cell count less 4000/mm3 20000/mm3 ; Suspected diagnose demyelinate disease central nervous system ( e.g . multiple sclerosis optic neuritis ) ; Systemic Lupus ; Non respect adequate wash period treatment might impact disease Any associated disease could impact study treatment intake Any condition , Investigator 's judgment would make subject unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>chronic plaque psoriasis , anti TNFα</keyword>
	<keyword>CDP870 , Cimzia</keyword>
</DOC>